Evidence map›Paper›PMID 29020145›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017

Interferon-γ-Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings.

Lucía Pastor, Aina Casellas, María Rupérez, Jorge Carrillo, Sonia Maculuve, Chenjerai Jairoce, Roger Paredes, Julià Blanco, Denise Naniche

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A Stronger Innate Immune Response During Hyperacute Human Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute Retroviral Syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lucía PastorISGlobal, Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona.
Aina CasellasISGlobal, Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona.
María RupérezISGlobal, Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona.
Jorge CarrilloISGlobal, Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona.
Sonia MaculuveCentro de Investigação em Saúde da Manhiça, Maputo, Mozambique.
Chenjerai JairoceCentro de Investigação em Saúde da Manhiça, Maputo, Mozambique.
Roger ParedesIrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol.
Julià BlancoIrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol.
Denise NanicheISGlobal, Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAchieving effective antiretroviral treatment (ART) monitoring is a key determinant to ensure viral suppression and reach the UNAIDS 90-90-90 targets. The gold standard for detecting virological failure is plasma human immunodeficiency virus (HIV) RNA (viral load [VL]) testing; however, its availability is very limited in low-income countries due to cost and operational constraints.

methodsHIV-1-infected adults on first-line ART attending routine visits at the Manhiça District Hospital, Mozambique, were previously evaluated for virologic failure. Plasma levels of interferon-γ-inducible protein 10 (IP-10) were quantified by enzyme-linked immunosorbent assay. Logistic regression was used to build an IP-10-based model able to identify individuals with VL >150 copies/mL. From the 316 individuals analyzed, 253 (80%) were used for model training and 63 (20%) for validation. Receiver operating characteristic curves were employed to evaluate model prediction.

resultsFrom the individuals included in the training set, 34% had detectable VL. Mean age was 41 years, 70% were females, and median time on ART was 3.4 years. IP-10 levels were significantly higher in subjects with detectable VL (108.2 pg/mL) as compared to those with undetectable VL (38.0 pg/mL) (P < .0001, U test). IP-10 univariate model demonstrated high classification performance (area under the curve = 0.85 [95% confidence interval {CI}, .80-.90]). Using a cutoff value of IP-10 ≥44.2 pg/mL, the model identified detectable VL with 91.9% sensitivity (95% CI, 83.9%-96.7%) and 59.9% specificity (95% CI, 52.0%-67.4%), values confirmed in the validation set.

conclusionsIP-10 is an accurate biomarker to screen individuals on ART for detectable viremia. Further studies should evaluate the benefits of IP-10 as a triage approach to monitor ART in resource-limited settings.

Indexed as

AdultAnti-Retroviral AgentsChemokine CXCL10Cross-Sectional StudiesFemaleHIV-1HIV InfectionsHumansMaleMozambiqueRNA, ViralROC CurveTreatment OutcomeViral LoadViremiaAnti-Retroviral AgentsChemokine CXCL10RNA, Viralcytokinesglobal healthimplementation researchscale-up viral loadsub-Saharan Africa

Identifiers

PMID29020145
PMCPMC5850521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.